Jasper Therapeutics
Presence
Acquisition, funding and merger involving Jasper Therapeutics.
- Jasper Therapeutics has just announced a $90 Million fundraising (posted on January 31 2023).
Executives
View the org chart displaying its 18 main executives
Most searched biographies at Jasper Therapeutics
Popular executive movements at Jasper Therapeutics
- Thomas Wiggans has joined the company as Chairman of the Board (posted on November 1 2023).
- Bill Lis, Chairman of the Board, has left the company (posted on November 1 2023).
- Jeet Mahal who was Chief Operating and Financial Officer, becomes Chief Operating Officer (posted on September 26 2023).
Click here to view some more movements at Jasper Therapeutics
Create your alert
to follow the executive moves at Jasper Therapeutics.
Biotechnology
Jasper Therapeutics has 2,275 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
- Nurix Therapeutics has just announced a $175 Million fundraising (posted on April 13 2024).
Popular contacts in Biotechnology
News
Press releases by Jasper Therapeutics
- News Releases | Jasper Therapeutics, Inc
- Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene Therapy for the Treatment of Sickle Cell Disease
- Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant | Business Wire
- Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting | Business Wire
- Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic Granulomatous Disease | Business Wire
- Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation | Bus
- Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation | Business Wire
- Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JSP191 in Sickle Cell Disease | Business Wire
- Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation | Business Wire
- Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID | Business Wire
- View more press releases Close
Social media about Jasper Therapeutics
- Jasper Therapeutics on Wikipedia, Google News & Yahoo Finance
- Jasper Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Anna French 
Call Jasper Therapeutics at +1 165 ...
